Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.

Although differences in rwPFS-2L and rwPFS-3L between luminal and non-luminal subtypes did not reach statistical significance, the effect sizes observed—particularly in third line—suggest meaningful clinical divergence and warrant further investigation.

also in 111,027 other papers